Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia

Michele Baccarani, Giovanna Corbelli, Sante Tura, S. Tura, G. Corbelli, M. Fiacchini, M. Gobbi, L. Gugliotta, F. Lauria, P. Ricci, A. Zaccaria, M. Baccarani, F. Mandelli, G. Alimena, G. Papa, L. Annino, G. Guglielmi, F. Salinas, M. F. Martelli, M. TonatoM. Soldani, G. De Sandre, G. Cetto, G. Pizzolo, G. Perona, F. De Cataldo, G. Panzacchi, R. Giustolisi, R. Musso, V. Raimondo, E. Cacciola, A. Cajozzo, P. Di Marco, P. Citarrella, A. Porcellini, T. Izzi, A. Manna, G. Lucarelli, P. Rossi Ferrini, F. Leoni, F. Salti, M. Bosisio, E. Lanzi, C. A. Dinelli, R. Di Guglielmo, A. Miliani, G. Torlontano, L. Geraci, G. D. Palka, L. Bruzzese, A. Abbadessa, G. Nappi, V. Rizzoli, A. Delsignore, P. Sansoni, C. Carnevali, A. Bonati, C. Quarantelli, S. Monjardini, E. Bajetta, R. Buzzoni, G. Broccia, A. Alberti, S. Magro, R. Battista, T. Barbui, E. Dini, F. Grignani, M. Liberati, A. Allegra

Research output: Contribution to journalArticlepeer-review


The effect of early splenectomy and of polychemotherapy with hydroxyurea, busulfan, and alternate bimonthly courses of arabinosyl cytosine and vincristine plus prednisone, was evaluated in 139 previously untreated patients with chronic myeloid leukemia (CML), consecutively admitted to 18 hospitals from March 1973 to October 1974. Fifty-six patients were splenectomized and 83 patients were not splenectomized. Splenectomy did not influence the duration of chronic and blastic phase, and did not prolong survival. The prognosis of high risk patients was not improved. During the chronic phase, high platelet counts were more frequent in splenectomy group, and five patients developed thrombotic or thromboembolic complications, 5 to 19 months after the operation. The median survival of the whole group was 50 months, with 32 of 139 patients (actuarial proportion 30%) remaining alive 72 months after diagnosis, but the slope of the survival curve was similar to that of historical controls. The results of this trial suggests that new strategies should be developed for the therapy of CML.

Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalLeukemia Research
Issue number2
Publication statusPublished - 1981


  • arabinosyl cytosine
  • Chronic myeloid leukemia
  • spleen
  • splenectomy
  • vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this